New York State Common Retirement Fund reduced its position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 0.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,900 shares of the biopharmaceutical company’s stock after selling 1 shares during the quarter. New York State Common Retirement Fund owned 0.07% of Esperion Therapeutics worth $736,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Emory University bought a new stake in Esperion Therapeutics during the second quarter worth $2,164,000. Nationwide Fund Advisors raised its position in Esperion Therapeutics by 25.5% during the second quarter. Nationwide Fund Advisors now owns 49,299 shares of the biopharmaceutical company’s stock worth $2,282,000 after acquiring an additional 10,013 shares in the last quarter. TIAA CREF Investment Management LLC raised its position in Esperion Therapeutics by 3.0% during the second quarter. TIAA CREF Investment Management LLC now owns 39,074 shares of the biopharmaceutical company’s stock worth $1,808,000 after acquiring an additional 1,148 shares in the last quarter. Teachers Advisors LLC raised its position in Esperion Therapeutics by 382.0% during the second quarter. Teachers Advisors LLC now owns 142,483 shares of the biopharmaceutical company’s stock worth $6,594,000 after acquiring an additional 112,920 shares in the last quarter. Finally, Alliancebernstein L.P. raised its position in Esperion Therapeutics by 5.3% during the second quarter. Alliancebernstein L.P. now owns 30,070 shares of the biopharmaceutical company’s stock worth $1,392,000 after acquiring an additional 1,500 shares in the last quarter. 90.05% of the stock is currently owned by hedge funds and other institutional investors.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) opened at $47.60 on Thursday. Esperion Therapeutics, Inc. has a one year low of $9.51 and a one year high of $57.40.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.07). During the same quarter last year, the business posted ($0.77) EPS. equities research analysts expect that Esperion Therapeutics, Inc. will post -7.12 earnings per share for the current fiscal year.

ESPR has been the topic of several analyst reports. Stifel Nicolaus reaffirmed a “buy” rating and set a $70.00 price target on shares of Esperion Therapeutics in a research report on Wednesday, October 4th. Northland Securities reaffirmed a “buy” rating and set a $72.00 price target on shares of Esperion Therapeutics in a research report on Wednesday, October 4th. Deutsche Bank AG set a $64.00 price objective on shares of Esperion Therapeutics and gave the company a “buy” rating in a research report on Wednesday, August 9th. Jefferies Group LLC raised shares of Esperion Therapeutics from a “hold” rating to a “buy” rating and dropped their price objective for the company from $85.00 to $55.00 in a research report on Tuesday, August 8th. Finally, BidaskClub lowered shares of Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 4th. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $58.92.

TRADEMARK VIOLATION WARNING: This report was first reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.dailypolitical.com/2017/11/09/new-york-state-common-retirement-fund-has-736000-holdings-in-esperion-therapeutics-inc-espr.html.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.